These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD, EuroSIDA study group. HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766 [Abstract] [Full Text] [Related]
3. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. Olsen CH, Gatell J, Ledergerber B, Katlama C, Friis-Møller N, Weber J, Horban A, Staszewski S, Lundgren JD, Phillips AN, EuroSIDA Study Group. AIDS; 2005 Feb 18; 19(3):319-30. PubMed ID: 15718843 [Abstract] [Full Text] [Related]
10. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency. Kousignian I, Abgrall S, Grabar S, Mahamat A, Teicher E, Rouveix E, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV. Clin Infect Dis; 2008 Jan 15; 46(2):296-304. PubMed ID: 18171266 [Abstract] [Full Text] [Related]
11. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, Reiss P, Egger M, Antiretroviral Therapy Cohort Collaboration. Arch Intern Med; 2005 Feb 28; 165(4):416-23. PubMed ID: 15738371 [Abstract] [Full Text] [Related]
14. Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy. Berenguer J, Alejos B, Hernando V, Viciana P, Salavert M, Santos I, Gómez-Sirvent JL, Vidal F, Portilla J, Del Amo J, CoRIS (AIDS Research Network Cohort). AIDS; 2012 Nov 13; 26(17):2241-6. PubMed ID: 22781223 [Abstract] [Full Text] [Related]
15. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, Kirk O, Lazzarin A, Wiercinska-Drapalo A, Karlsson A, Lundgren JD, EuroSIDA Study Group. AIDS; 2008 Oct 18; 22(16):2187-98. PubMed ID: 18832882 [Abstract] [Full Text] [Related]
17. Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART. Podlekareva D, Mocroft A, Kirk O, Reiss P, Aldins P, Katlama C, Kovari H, Stellbrink HJ, D'Arminio Monforte A, Lundgren JD, Eurosida Study Group. Scand J Infect Dis; 2008 Oct 18; 40(11-12):908-13. PubMed ID: 18609197 [Abstract] [Full Text] [Related]
18. Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment. Zhang S, van Sighem A, Gras L, Reiss P, Smit C, Kroon F, Jurriaans S, Prins J, Lange J, de Wolf F. Antivir Ther; 2010 Oct 18; 15(4):555-62. PubMed ID: 20587848 [Abstract] [Full Text] [Related]